Our vision is to build the largest, independent vaccine company either through bringing products to market from our own research and development pipeline or through acquisition and in-licensing transactions.
Our primary focus is on the development and commercialization of vaccines for the overlooked, traveler segment. We have commercially available vaccines to help protect travelers against typhoid and cholera and in development for adenovirus, anthrax, cholera, hepatitis A, HIV, and zika.
Travel vaccines are not only important for the developed world, but these vaccines can also be of benefit for the developing world to protect against endemic infectious disease. We are working to ensure our vaccines are available to broader populations most affected by diseases such as cholera.